Anteris Technologies (ASX:AVR) - Chief Executive, Wayne Paterson
Chief Executive, Wayne Paterson
Source: Anteris Technologies (Twitter)
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Anteris Technologies (AVR) enters trading halt ahead of an upcoming capital raise
  • It is not known to the market how much the company is aiming to raise or where the money will be spent
  • Under the halt, company shares will be paused until Thursday, March 3, or when further details about the raise are released to the market
  • On the market, Anteris last traded at $18.67 per share

Anteris Technologies (AVR) has started the week in a trading halt ahead of an upcoming capital raise.

So far, it is unknown how much the company is aiming to raise or where the funds will be spent.

AVR shares will be paused until Thursday, March 3, or when further details about the raise are released to the market.

Anteris is an Australian based structural heart company that is developing solutions that help healthcare professionals.

Earlier this year, the company reported “excellent” results from the first-in-human trial of its DurAVR replacement heart valve.

Anteris surgically installed the valve in five patients of a 10-patient trial, with positive results recorded at the 30-day follow up point.

Chief Medical Officer Chris Meduri, who led the study, said the exercise performance indicated early improvements in the quality of life in patients who received the DurAVR valve.

On the market, Anteris last traded at $18.67 per share.

AVR by the numbers
More From The Market Herald
The Market Herald Video

" Steadfast (ASX:SDF) reveals $250m cap raise and $301m acquisition of IBA

Multi-billion-dollar insurance company Steadfast Group (ASX:SDF) is raising up to $250 million to fund the Trapped…

" DevEx Resources (ASX:DEV) to raise fresh funds

DevEx Resources (ASX:DEV) has entered a trading halt as the company prepares to raise new funds.